Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

Please share Science & Enterprise

Gut-Brain Meds Developer Going Public in Merger

Milk splashing

(Myriams-Fotos, Pixabay. https://pixabay.com/photos/milk-splash-drops-food-liquid-4755234/)

31 Oct. 2022. A developer of synthetic biology treatments for inflammatory and neurological disorders linked to the gut is becoming a public company through a special acquisition merger. Intrinsic Medicine Inc. in Seattle is joining with Phoenix Biotech Acquisition Corp. in Oakland, California, a special purpose acquisition company or SPAC, . . . → Read More: Gut-Brain Meds Developer Going Public in Merger

Digital Mental Therapy Company to Go Public in Merger

Child with computer tablet

A creator of game therapies for cognitive impairments is becoming a publicly-traded company through a special purpose acquisition company or SPAC. . . . → Read More: Digital Mental Therapy Company to Go Public in Merger

Synthetic Antibody Company Goes Public in $230M Merger

Four fist bump

A developer of synthetic antibodies for inflammatory and skin disorders is becoming a public company through a special purpose acquisition-merger. . . . → Read More: Synthetic Antibody Company Goes Public in $230M Merger

RNA Manufacturer Goes Public in $282M Merger

Bumble bee and flower

A company producing synthetic RNA for agricultural and biomedical applications is now a public company after a special-purpose acquisition. . . . → Read More: RNA Manufacturer Goes Public in $282M Merger

Synthetic Bio Company Goes Public in $2.5B Merger

Investment graphic

A company developing synthetic biology and engineering tools for biotechnology is becoming a public company through a special-purpose acquisition. . . . → Read More: Synthetic Bio Company Goes Public in $2.5B Merger

Biomanufacturing Materials Company Issues $500M IPO

Wall Street sign

Zymergen Inc., a developer of materials made with synthetic biology for industrial products is raising $500 million in its initial public stock offering. . . . → Read More: Biomanufacturing Materials Company Issues $500M IPO

Engineered Cell Therapy Company Issues $588M IPO

NASDAQ share price display

A company developing regenerative therapies with engineered stem cells for cancer and other diseases is raising $587.5 million in its initial public offering or IPO. . . . → Read More: Engineered Cell Therapy Company Issues $588M IPO

2020 Venture Funds Mixed, Biotech Keeps Sizzling

2020 venture transactions

Total venture investments in dollars jumped to a new high in the U.S., while biotechnology remained the single hottest sector in 2020. . . . → Read More: 2020 Venture Funds Mixed, Biotech Keeps Sizzling

Covid-19 Antibody Developer Raises $483M in IPO

Wall Street sign

A biotechnology company developing therapeutic antibodies for Covid-19 infections is raising $483 million in its initial public offering of common stock. . . . → Read More: Covid-19 Antibody Developer Raises $483M in IPO

Venture Rounds, IPOs, Mergers Vanish in Election Week

White House

Nationwide jitters in the U.S. appear to be affecting venture capital activities in the week of the presidential and congressional elections. . . . → Read More: Venture Rounds, IPOs, Mergers Vanish in Election Week